Quantisnow Logo
Dashboard

SEC Form SC 13G/A filed by Chinook Therapeutics Inc. (Amendment)

$KDNY
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $KDNY alert in real time by email
SC 13G/A 1 d431875dsc13ga.htm SC 13G/A SC 13G/A

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

Chinook Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

16961L 106

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 16961L 106

 

  1.    

  Names of Reporting Persons

 

  Frazier Life Sciences Public Fund, L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

    5.     

  Sole Voting Power

 

  0 shares

   6.   

  Shared Voting Power

 

  3,128,211 shares (1)

   7.   

  Sole Dispositive Power

 

  0 shares

   8.   

  Shared Dispositive Power

 

  3,128,211 shares (1)

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  3,128,211 shares (1)

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

  ☐

11.  

  Percent of Class Represented by Amount in Row 9

 

  4.9% (2)

12.  

  Type of Reporting Person (see instructions)

 

  PN

 

(1)

Consists of 3,128,211 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)

Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

 

  1.    

  Names of Reporting Persons

 

  FHMLSP, L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

    5.     

  Sole Voting Power

 

  0 shares

   6.   

  Shared Voting Power

 

  3,128,211 shares (1)

   7.   

  Sole Dispositive Power

 

  0 shares

   8.   

  Shared Dispositive Power

 

  3,128,211 shares (1)

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  3,128,211 shares (1)

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

  ☐

11.  

  Percent of Class Represented by Amount in Row 9

 

  4.9% (2)

12.  

  Type of Reporting Person (see instructions)

 

  PN

 

(1)

Consists of 3,128,211 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)

Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

 

  1.    

  Names of Reporting Persons

 

  FHMLSP, L.L.C.

  2.  

  Check the Appropriate Box if a Member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

    5.     

  Sole Voting Power

 

  0 shares

   6.   

  Shared Voting Power

 

  3,128,211 shares (1)

   7.   

  Sole Dispositive Power

 

  0 shares

   8.   

  Shared Dispositive Power

 

  3,128,211 shares (1)

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  3,128,211 shares (1)

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

  ☐

11.  

  Percent of Class Represented by Amount in Row 9

 

  4.9% (2)

12.  

  Type of Reporting Person (see instructions)

 

  OO

 

(1)

Consists of 3,128,211 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)

Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

 

  1.    

  Names of Reporting Persons

 

  Frazier Life Sciences X, L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

    5.     

  Sole Voting Power

 

  0 shares

   6.   

  Shared Voting Power

 

  924,299 shares (1)

   7.   

  Sole Dispositive Power

 

  0 shares

   8.   

  Shared Dispositive Power

 

  924,299 shares (1)

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  924,299 shares (1)

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

  ☐

11.  

  Percent of Class Represented by Amount in Row 9

 

  1.4% (2)

12.  

  Type of Reporting Person (see instructions)

 

  PN

 

(1)

Consists of 924,299 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)

Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

 

  1.    

  Names of Reporting Persons

 

  FHMLS X, L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

    5.     

  Sole Voting Power

 

  0 shares

   6.   

  Shared Voting Power

 

  924,299 shares (1)

   7.   

  Sole Dispositive Power

 

  0 shares

   8.   

  Shared Dispositive Power

 

  924,299 shares (1)

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  924,299 shares (1)

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

  ☐

11.  

  Percent of Class Represented by Amount in Row 9

 

  1.4% (2)

12.  

  Type of Reporting Person (see instructions)

 

  PN

 

(1)

Consists of 924,299 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)

Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

 

  1.    

  Names of Reporting Persons

 

  FHMLS X, L.L.C.

  2.  

  Check the Appropriate Box if a Member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

    5.     

  Sole Voting Power

 

  0 shares

   6.   

  Shared Voting Power

 

  924,299 shares (1)

   7.   

  Sole Dispositive Power

 

  0 shares

   8.   

  Shared Dispositive Power

 

  924,299 shares (1)

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  924,299 shares (1)

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

  ☐

11.  

  Percent of Class Represented by Amount in Row 9

 

  1.4% (2)

12.  

  Type of Reporting Person (see instructions)

 

  OO

 

(1)

Consists of 924,299 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)

Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

 

  1.    

  Names of Reporting Persons

 

  James N. Topper

  2.  

  Check the Appropriate Box if a Member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  United States Citizen

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

    5.     

  Sole Voting Power

 

  0 shares

   6.   

  Shared Voting Power

 

  4,052,510 shares (1)

   7.   

  Sole Dispositive Power

 

  0 shares

   8.   

  Shared Dispositive Power

 

  4,052,510 shares (1)

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  4,052,510 shares (1)

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

  ☐

11.  

  Percent of Class Represented by Amount in Row 9

 

  6.3% (2)

12.  

  Type of Reporting Person (see instructions)

 

  IN

 

(1)

Consists of (i) 3,128,211 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 924,299 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)

Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

 

  1.    

  Names of Reporting Persons

 

  Patrick J. Heron

  2.  

  Check the Appropriate Box if a Member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  United States Citizen

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

    5.     

  Sole Voting Power

 

  0 shares

   6.   

  Shared Voting Power

 

  4,052,510 shares (1)

   7.   

  Sole Dispositive Power

 

  0 shares

   8.   

  Shared Dispositive Power

 

  4,052,510 shares (1)

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  4,052,510 shares (1)

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

  ☐

11.  

  Percent of Class Represented by Amount in Row 9

 

  6.3% (2)

12.  

  Type of Reporting Person (see instructions)

 

  IN

 

(1)

Consists of (i) 3,128,211 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 924,299 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)

Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

 

  1.    

  Names of Reporting Persons

 

  Albert Cha

  2.  

  Check the Appropriate Box if a Member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  United States Citizen

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

    5.     

  Sole Voting Power

 

  0 shares

   6.   

  Shared Voting Power

 

  3,128,211 shares (1)

   7.   

  Sole Dispositive Power

 

  0 shares

   8.   

  Shared Dispositive Power

 

  3,128,211 shares (1)

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  3,128,211 shares (1)

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

  ☐

11.  

  Percent of Class Represented by Amount in Row 9

 

  4.9% (2)

12.  

  Type of Reporting Person (see instructions)

 

  IN

 

(1)

Consists of 3,128,211 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)

Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

 

  1.    

  Names of Reporting Persons

 

  James Brush

  2.  

  Check the Appropriate Box if a Member of a Group (see instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  United States Citizen

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

    5.     

  Sole Voting Power

 

  0 shares

   6.   

  Shared Voting Power

 

  3,128,211 shares (1)

   7.   

  Sole Dispositive Power

 

  0 shares

   8.   

  Shared Dispositive Power

 

  3,128,211 shares (1)

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  3,128,211 shares (1)

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

  ☐

11.  

  Percent of Class Represented by Amount in Row 9

 

  4.9% (2)

12.  

  Type of Reporting Person (see instructions)

 

  IN

 

(1)

Consists of 3,128,211 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)

Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

Item 1(a).    Name of Issuer: Chinook Therapeutics, Inc.
Item 1(b).    Address of Issuer’s Principal Executive Offices: 400 Fairview Avenue North, Suite 900, Seattle, Washington 98102
Item 2(a).   

Name of Person Filing:

 

The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

 

Frazier Life Sciences Public Fund, L.P. (“FLSPF”)

FHMLSP, L.P.

FHMLSP, L.L.C.

Frazier Life Sciences X, L.P. (“FLS X”)

FHMLS X, L.P.

FHMLS X, L.L.C.

James N. Topper (“Topper”)

Patrick J. Heron (“Heron”)

Albert Cha (“Cha”)

James Brush (“Brush” and together with Topper, Heron and Cha, the “Members”)

Item 2(b).   

Address of Principal Business Office or, if none, Residence:

 

The address and principal business office of the Reporting Persons is:

 

c/o Frazier Life Sciences Management, L.P.

70 Willow Road, Suite 200

Menlo Park, CA 94025

Item 2(c).    Citizenship:

 

Entities:    FLSPF    –    Delaware, U.S.A.
   FHMLSP, L.P.    –    Delaware, U.S.A.
   FHMLSP, L.L.C.    –    Delaware, U.S.A.
   FLS X    –    Delaware, U.S.A.
   FHMLS X, L.P.    –    Delaware, U.S.A.
   FHMLS X, L.L.C.    –    Delaware, U.S.A.
Individuals:    Topper    –    United States Citizen
   Heron    –    United States Citizen
   Cha    –    United States Citizen
   Brush    –    United States Citizen

 

Item 2(d).    Title of Class of Securities: Common Stock
Item 2(e).    CUSIP Number: 16961L 106
Item 3.    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)

  

☐

    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)

  

☐

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

  

☐

    Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)

  

☐

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

  

☐

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

  

☐

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

  

☐

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)

  

☐

    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

   ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

   ☐    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)

   ☐    Group, in accordance with §240.13d–1(b)(1)(ii)(K).
  If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

 

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

 

  (a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

 

  (b)

Percent of Class: See Row 11 of cover page for each Reporting Person

 

  (c)

Number of shares as to which the person has:

 

  (i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

 

  (ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

 

  (iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

 

  (iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

 

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

 

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on the signature page to this Schedule 13G amendment.

 

Item 9.

Notice of Dissolution of a Group

Not applicable.

 

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 14, 2023     FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
    By: FHMLSP, L.P., its General Partner
    By: FHMLSP, L.L.C., its General Partner
    By:  

/s/ Steve R. Bailey

      Steve R. Bailey, Chief Financial Officer
Date: February 14, 2023     FHMLSP, L.P.
    By: FHMLSP, L.L.C., its General Partner
    By:  

/s/ Steve R. Bailey

      Steve R. Bailey, Chief Financial Officer
Date: February 14, 2023     FHMLSP, L.L.C.
    By:  

/s/ Steve R. Bailey

      Steve R. Bailey, Chief Financial Officer
Date: February 14, 2023     FRAZIER LIFE SCIENCES X, L.P.
    By: FHMLS X, L.P., its General Partner
    By: FHMLS X, L.L.C., its General Partner
    By:  

/s/ Steve R. Bailey

      Steve R. Bailey, Chief Financial Officer
Date: February 14, 2023     FHMLS X, L.P.
    By: FHMLS X, L.L.C., its General Partner
    By:  

/s/ Steve R. Bailey

      Steve R. Bailey, Chief Financial Officer
Date: February 14, 2023     FHMLS X, L.L.C.
    By:  

/s/ Steve R. Bailey

      Steve R. Bailey, Chief Financial Officer
Date: February 14, 2023     By:  

*

      James N. Topper
Date: February 14, 2023     By:  

*

      Patrick J. Heron
Date: February 14, 2023     By:  

**

      Albert Cha
Date: February 14, 2023     By:  

**

      James Brush

Date: February 14, 2023     By:  

/s/ Steve R. Bailey

      Steve R. Bailey, as Attorney-in-Fact

 

*

This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

 

**

This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

Get the next $KDNY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$KDNY

DatePrice TargetRatingAnalyst
8/8/2023$42.00Outperform → Neutral
Wedbush
3/6/2023$41.00Overweight
Piper Sandler
3/1/2023$43.00Buy
Guggenheim
12/5/2022$30.00Overweight
Wells Fargo
6/28/2022$30.00Buy
Stifel
More analyst ratings

$KDNY
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

    SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody. "Initiation of the phase 3 BEYOND study is an important step towards our goal of providing an innovative treatment option for patients with IgAN, a disease with high unmet need and limited treatment options," said E

    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Lifshitz Law PLLC Announces Investigations of BG, KDNY, QUOT, and DICE

    NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Bunge Limited (NYSE:BG) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock. If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-m

    $BG
    $DICE
    $KDNY
    $QUOT
    Packaged Foods
    Consumer Staples
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

    CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 daysPharmacokinetics (PK) was well characterized with dose-proportional exposures and a half-life that supports once-daily dosingSuccessful implementation of a novel 13C2-glycolate tracer established proof-of-mechanism of CHK-336 to block hepatic oxalate production in HVsOne serious adverse event (SAE) of anaphylaxis occurred in a multiple ascending dose HV who received one 125 mg dose CHK-336, resulting in voluntary study pauseAdditional research presented on the impact of maladaptive tubular epithelial cells on progression of chronic kidney disease S

    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KDNY
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$KDNY
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$KDNY
 SEC Filings

See more

$KDNY
 Leadership Updates

Live Leadership Updates

See more

  • Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates

    SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates. "During the first quarter of 2023, we continued to advance our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We recently completed full enrollment of the phase 3 ALIGN clinical trial, are on track to initiate the phase 3 BION-1301 IgAN clinical trial mid-year and expect to report topline ALIGN results in the fourth quarter of thi

    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors

    SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 20 years of executive leadership and commercial experience in the biopharmaceutical industry to Chinook. "We are thrilled to welcome Bob to Chinook's board of directors as we advance our pipeline through key milestones in 2023 and beyond," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Bob brings significant industry experience in bu

    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer

    SEATTLE, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Andrew Oxtoby as chief commercial officer. "We are pleased to welcome Andrew to Chinook as we prepare for a year of important milestones for our atrasentan and BION-1301 programs," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Andrew is an accomplished industry leader with more than 20 years of global biopharmaceutical experience and a proven track record of building commercial strategies and executing n

    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KDNY
 Financials

Live finance-specific insights

See more

  • Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

    Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond to clinically meaningful proteinuria reductions in patients with IgAN across Cohorts 1 and 2Zigakibart is well-tolerated, with no ADAs observed or treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2 In all patients combined from both Cohorts 1 and 2, zigakibart demonstrated mean proteinuria reductions of 20% at 12 weeks of treatment, 39% at 24 weeks of treatment and 67% at 52 weeks of treatmentExtended treatment with zigakibart resulted in sustained clinical benefit, with 67% mean proteinuria

    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress

    Updated interim data to be presented from Cohort 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgANInitial data to be presented from the phase 1 study of CHK-336 in healthy volunteersAdditional presentations on the design of the phase 2 ASSIST study for atrasentan in patients with IgAN on background RASi and SGLT2i and the phase 3 BEYOND study of BION-1301 in patients with IgAN, as well as research on the impact of maladaptive tubular epithelial cells on disease progression in chronic kidney diseasesChinook to host investor conference call and webcast on June 16, 2023 at 8:15 am EDT to review and discuss the presentations and provide corporate updates SEATTLE, May 05

    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022

    The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and proteinuria reductionsBION-1301 is well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2BION-1301 continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, in patients with IgAN across Cohorts 1 and 2In Cohort 1, BION-1301 demonstrated mean proteinuria reductions of 30.4% at 12 weeks of treatment, 48.8% at 24 weeks of treatment and 66.9% at 52 weeks of treatment, as well as 6

    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KDNY
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more